Relaxin gene therapy: A promising new treatment option for various diseases with aberrant fibrosis or irregular angiogenesis
- Authors
- Hong, JinWoo; Yun, Chae-Ok
- Issue Date
- May-2019
- Publisher
- ELSEVIER IRELAND LTD
- Keywords
- Relaxin; Gene therapy; Cardiac dysfunction; Cancer; Liver cirrhosis
- Citation
- MOLECULAR AND CELLULAR ENDOCRINOLOGY, v.487, pp.80 - 84
- Indexed
- SCIE
SCOPUS
- Journal Title
- MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Volume
- 487
- Start Page
- 80
- End Page
- 84
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/4573
- DOI
- 10.1016/j.mce.2019.01.009
- ISSN
- 0303-7207
- Abstract
- Relaxin (RLX) is an insulin-like polypeptide hormone that was initially introduced for its pregnancy-related function. Subsequent studies revealed that RLX possesses anti-fibrotic functions in tumors and nonreproductive tissues, such as skin, lungs, and others. This aspect of the RLX has been explored for the treatment of various illnesses, such as cardiac fibrosis, liver fibrosis, and solid tumors. With gene therapy coming into age with increasing number of products being approved by regulatory bodies in Europe and United States, we aim to discuss how RLX have been utilized in scope of gene therapy for treatment of various illnesses.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 공과대학 > 서울 생명공학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/4573)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.